Focused Ultrasound System for Neurosurgery Market Analysis, Size, Share, Growth, Trends, and Forecasts by 2031
The Focused Ultrasound System for Neurosurgery market is an innovative and minimally invasive therapeutic technology gaining significance in neurological treatment. Focused ultrasound surgery is a novel technique that utilizes focused ultrasonic energy for the ablation or disruption of diseased tissue in the brain or spine. Focused ultrasound neurosurgery involves a transducer delivering focused ultrasonic waves to a precise target in the body without causing damage to overlying or adjacent tissue structures. This allows for a completely non-invasive approach to treat essential tremor, Parkinson's disease, neuropathic pain and tumors in the brain and spine.
??? ? ???? ?????? ??????:https://www.metastatinsight.com/request-sample/2482
Top Companies
-
INSIGHTEC Ltd.
-
Carthera S.A.
-
Neurosona Co., Ltd.
-
FUS Instruments Inc.
-
Sonic Concepts, Inc. (NeuroFUS)
-
BrainSonix Corporation
-
NaviFUS Corporation
?????? @https://www.metastatinsight.com/report/focused-ultrasound-system-for-neurosurgery-market
Compared to traditional open surgery or radiation therapy, focused ultrasound neurosurgery is important for its potential to improve clinical outcomes, reduce risk and length of hospitalization and improve quality of life for patients. The technology can reach abnormalities previously considered inoperable and enables treatment without general anesthesia or ionizing radiation.
Some key drivers of growth for this market include rising prevalence of neurological disorders, strong clinical evidence demonstrating safety and efficacy, and expanded regulatory approvals worldwide. As researchers continue to refine focused ultrasound techniques and expand its applications, this innovative technology holds genuine promise for transforming neurosurgery and improving patient care globally.
Global Focused Ultrasound System for Neurosurgery market is estimated to reach $82,718.1 Million by 2030; growing at a CAGR of 7.9% from 2023 to 2030.
Contact Us:
https://www.metastatinsight.com
inquiry@metastatinsight.com
+1 214 613 5758
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian